Smith+Nephew Lowers Revenue Forecast Despite Strong H1 Profit; Buyback Advances
SNN is trading near its 52-week low of $28.555 (7.5% above the low).
Summary
Smith+Nephew posted an 8.1% rise in H1 2026 trading profit to $566M, but softer Q2 sales forced a reduction in full-year revenue growth guidance to ~4% from ~6%. Profit and cash flow guidance were held steady, the dividend was increased, and the $500M buyback is progressing.
Key Events · Earnings and Guidance · SNN
-
Revenue Miss, Guidance Cut
Underlying revenue grew only 1.6% in Q2, missing expectations, as softness in US Orthopaedics and Advanced Wound Bioactives weighed on performance. Consequently, full-year revenue growth guidance was trimmed to ~4% from ~6%.
-
Profit Beat on Efficiency Gains
H1 trading profit climbed 8.1% to $566M, with the margin expanding 60bps to 18.3%, as $130M in efficiency savings more than compensated for the revenue shortfall. Full-year trading profit guidance of ~$1.3B was reaffirmed.
-
Buyback Progress & Dividend Hike
As of 3 August 2026, $216M of the $500M buyback program has been settled. Reflecting confidence in cash generation, the interim dividend was raised 4.0% to 15.6¢ per share.
-
Orthopaedics Challenges Persist
US Knee Implants declined 7.2% in Q2, hampered by portfolio gaps and the market's shift to cementless solutions; US Hip Implants fell 1.5% due to set deployment delays. Management expects new product launches to drive improvement in the second half.
Analysis · SNN · Industrial Applications And Services
Smith+Nephew's H1 2026 results were a study in contrasts: trading profit surged 8.1% on the back of efficiency gains, yet revenue growth fell short of expectations, prompting a cut in the full-year revenue growth outlook from ~6% to ~4%. The profit beat and the decision to maintain profit and cash guidance underscore that the 12-Point Plan is delivering, but the top-line softness—particularly in US Orthopaedics and wound bioactives—casts doubt on the RISE strategy's growth trajectory. With the $500M buyback on track ($216M settled) and the dividend raised 4%, management is signaling confidence in cash generation. Against the backdrop of activist Cevian Capital building a stake above 14%, these results will be closely parsed for evidence of an operational turnaround or mounting pressure for strategic change.
At the time of this filing, SNN was trading at $30.70 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $28.56 to $38.79. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.